About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Metastatic Melanoma Patients’ Response to Immunotherapy can be Predicted With a Protein

by Shirley Johanna on May 6, 2016 at 3:45 PM
Font : A-A+

Metastatic Melanoma Patients’ Response to Immunotherapy can be Predicted With a Protein

A protein called Bim can predict the response to immunotherapy for patients with metastatic melanoma, says a study by Mayo Clinic researchers led by senior author Haidong Dong, M.D., Ph.D.

"Immune checkpoint therapy with PD-1 blockade has emerged as an effective treatment for many advanced cancers," says the study's lead author, Roxana Dronca, M.D., an oncologist at Mayo Clinic. "However, only a fraction of patients achieve durable responses to immunotherapy and, to date, we have had no means of predicting which patients are most likely to benefit."

Advertisement


PD-1 blockade is a type of immunotherapy that helps make cancer cells more vulnerable to attack by T cells in the body's immune system by blocking the activity of a molecule called PD-1. PD-1 prevents T cells from recognizing and attacking cancer cells.

Dr. Dronca and her colleagues found a higher frequency of immune cells, called T cells, which expressed the protein Bim among patients who responded to immunotherapy for metastatic melanoma than among patients who were treated immunotherapy but whose disease had progressed.
Advertisement

"Our previous research demonstrated that Bim is a downstream signaling molecule in the PD-1 signaling pathway, and that levels of Bim reflect the degree of PD-1 interaction with its ligand PD-L1," says Dr. Dong.

A signaling pathway is a group of molecules in a cell that works together to control one or more cell functions, such as cell division or cell death.

"We hypothesized that the increased frequency of CD8+PD-1+Bim+T cells in patients who respond to immunotherapy reflects an increased number of target T cells for PD-1 blockade with pembrolizumab, which may explain the positive clinical outcomes in these patients," Dr. Dong says.

"A great advantage of this approach lies in the ease of serial peripheral blood testing, compared with repeated invasive tissue biopsies," says Dr. Dronca. "We are currently validating these results in a larger prospective cohort of patients with metastatic melanoma and in patients with lung cancer using multiple serial peripheral blood samples and standardized tumor assessment."

For the study, Dr. Dronca and her colleagues collected peripheral blood from patients at the initiation immunotherapy (baseline) and again at the time of first radiographic tumor assessment (12 weeks). They collected additional samples at each subsequent radiographic tumor evaluation for patients continuing on immunotherapy.

"The potential discovery of a way to predict a patient's response to pembrolizumab would help inform clinical decision-making," said Dr. Dronca. "It would not only help clinicians identify which patients would be most likely to benefit from the drug, but also prevent patients not likely to respond to the therapy from being exposed to unnecessary toxicities and costs."

The study is published online in JCI Insight.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Get Involved and Stand Up for Human Rights on Human Rights Day 2022
Coronary Artery Bypass Grafting
Macronutrients Calculator for Weight Loss
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Skin Cancer Immunisation Ultra-Violet Radiation Amyotrophic Lateral Sclerosis (ALS) Dealing with Pollen Allergy Magical Millets for Your Health Melanoma Diet and Nutrition Tips for Athletes Nutrition IQ Immune Checkpoint Inhibitors for Cancer Treatment 

Most Popular on Medindia

Loram (2 mg) (Lorazepam) Calculate Ideal Weight for Infants Post-Nasal Drip Daily Calorie Requirements A-Z Drug Brands in India Diaphragmatic Hernia Find a Hospital Selfie Addiction Calculator Iron Intake Calculator Blood Pressure Calculator
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Metastatic Melanoma Patients’ Response to Immunotherapy can be Predicted With a Protein Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests